TY - JOUR
T1 - Universal health coverage and intersectoral action for health
T2 - key messages from Disease Control Priorities, 3rd edition
AU - Jamison, Dean T.
AU - Alwan, Ala
AU - Mock, Charles N.
AU - Nugent, Rachel
AU - Watkins, David
AU - Adeyi, Olusoji
AU - Anand, Shuchi
AU - Atun, Rifat
AU - Bertozzi, Stefano
AU - Bhutta, Zulfiqar
AU - Binagwaho, Agnes
AU - Black, Robert
AU - Blecher, Mark
AU - Bloom, Barry R.
AU - Brouwer, Elizabeth
AU - Bundy, Donald A.P.
AU - Chisholm, Dan
AU - Cieza, Alarcos
AU - Cullen, Mark
AU - Danforth, Kristen
AU - de Silva, Nilanthi
AU - Debas, Haile T.
AU - Donkor, Peter
AU - Dua, Tarun
AU - Fleming, Kenneth A.
AU - Gallivan, Mark
AU - Garcia, Patricia J.
AU - Gawande, Atul
AU - Gaziano, Thomas
AU - Gelband, Hellen
AU - Glass, Roger
AU - Glassman, Amanda
AU - Gray, Glenda
AU - Habte, Demissie
AU - Holmes, King K.
AU - Horton, Susan
AU - Hutton, Guy
AU - Jha, Prabhat
AU - Knaul, Felicia M.
AU - Kobusingye, Olive
AU - Krakauer, Eric L.
AU - Kruk, Margaret E.
AU - Lachmann, Peter
AU - Laxminarayan, Ramanan
AU - Levin, Carol
AU - Looi, Lai Meng
AU - Madhav, Nita
AU - Mahmoud, Adel
AU - Mbanya, Jean Claude
AU - Measham, Anthony
AU - Medina-Mora, María Elena
AU - Medlin, Carol
AU - Mills, Anne
AU - Mills, Jody Anne
AU - Montoya, Jaime
AU - Norheim, Ole
AU - Olson, Zachary
AU - Omokhodion, Folashade
AU - Oppenheim, Ben
AU - Ord, Toby
AU - Patel, Vikram
AU - Patton, George C.
AU - Peabody, John
AU - Prabhakaran, Dorairaj
AU - Qi, Jinyuan
AU - Reynolds, Teri
AU - Ruacan, Sevket
AU - Sankaranarayanan, Rengaswamy
AU - Sepúlveda, Jaime
AU - Skolnik, Richard
AU - Smith, Kirk R.
AU - Temmerman, Marleen
AU - Tollman, Stephen
AU - Verguet, Stéphane
AU - Walker, Damian G.
AU - Walker, Neff
AU - Wu, Yangfeng
AU - Zhao, Kun
N1 - Funding Information:
DTJ, AA, CNM, RN, DGW, KD, and CL report grants from the Bill & Melinda Gates Foundation during the conduct of the study. KAF reports personal fees from the Centre for Global Health, National Cancer Institute during the conduct of the study. TG reports personal fees from Teva Pharmaceuticals and grants from United HealthCare Services and Novartis, outside the submitted work. FMK reports grants from Pfizer, Mayday Fund, American Cancer Society, Roche, CRDF Global, JM Foundation, Grunenthal, and GDS, during the conduct of the study; and grants, personal fees, and non-financial support from Roche, Pfizer, Novartis, GlaxoSmithKline, Merck/EMD Serono, Asociacion Mexicana de Industrias de Investigacion Farmaceutica, Sanofi, Chinoin, and NADRO, outside the submitted work. MEK reports personal fees from Merck for Mothers, outside the submitted work. DP reports grants from the University of Washington, during the conduct of the study. DAPB and DGW are employees of the Bill & Melinda Gates Foundation, and SB, CM, and JS have previously worked for the Bill & Melinda Gates Foundation, which funds the DCP3 series. DGW has managed the Disease Control Priorities Network grant since 2011. GH was previously affiliated with the Water and Sanitation Program, World Bank, Washington, DC, USA. DC, AC, TD, JM, and TR are staff members of the World Health Organization. The authors alone are responsible for the views expressed in this Review and they do not necessarily represent the decisions, policy, or views of the World Health Organization. All other authors declare no competing interests.
Funding Information:
The Bill & Melinda Gates Foundation funded DCP3 as an element of its Disease Control Priorities Network grant to the University of Washington. The views expressed herein are those of the authors and do not necessarily reflect the official policy or position of the Bill & Melinda Gates Foundation. Many institutions have made available the time of their staff and they are specifically acknowledged in each volume. The views expressed in this paper are those of individual authors and not of the institutions with which they are affiliated. We acknowledge three institutions that have played key roles in DCP3. One is the World Bank, original home for the DCP series and accomplished publisher of its products. Within the World Bank, Carlos Rossel and Mary Fisk oversaw the editing and publication of the series, and served as important champions for DCP3. The second is the Inter-Academy Medical Panel (IAMP) and its US affiliate, the National Academy of Medicine (NAM). IAMP/NAM have organised a peer-review process to cover chapters in the nine volumes, and they established an Advisory Committee to the Editors, chaired by Anne Mills, of enormous value. The Department of Global Health, University of Washington, has provided a congenial home for DCP for the past 5 years. We acknowledge the intellectual and practical support of the department's two chairs during this period, King Holmes and Judith Wasserheit. We thank Shamelle Richards, Tiffany Wilk, and Nazila Dabestani for their administrative and research support to the production of DCP3. Brianne Adderley has ably served DCP3 as Project Manager since the beginning, and we owe her a very particular thanks. We thank the referees for valuable and constructive comments.
Publisher Copyright:
© 2018 Elsevier Ltd
PY - 2018/3/17
Y1 - 2018/3/17
N2 - The World Bank is publishing nine volumes of Disease Control Priorities, 3rd edition (DCP3) between 2015 and 2018. Volume 9, Improving Health and Reducing Poverty, summarises the main messages from all the volumes and contains cross-cutting analyses. This Review draws on all nine volumes to convey conclusions. The analysis in DCP3 is built around 21 essential packages that were developed in the nine volumes. Each essential package addresses the concerns of a major professional community (eg, child health or surgery) and contains a mix of intersectoral policies and health-sector interventions. 71 intersectoral prevention policies were identified in total, 29 of which are priorities for early introduction. Interventions within the health sector were grouped onto five platforms (population based, community level, health centre, first-level hospital, and referral hospital). DCP3 defines a model concept of essential universal health coverage (EUHC) with 218 interventions that provides a starting point for country-specific analysis of priorities. Assuming steady-state implementation by 2030, EUHC in lower-middle-income countries would reduce premature deaths by an estimated 4·2 million per year. Estimated total costs prove substantial: about 9·1% of (current) gross national income (GNI) in low-income countries and 5·2% of GNI in lower-middle-income countries. Financing provision of continuing intervention against chronic conditions accounts for about half of estimated incremental costs. For lower-middle-income countries, the mortality reduction from implementing the EUHC can only reach about half the mortality reduction in non-communicable diseases called for by the Sustainable Development Goals. Full achievement will require increased investment or sustained intersectoral action, and actions by finance ministries to tax smoking and polluting emissions and to reduce or eliminate (often large) subsidies on fossil fuels appear of central importance. DCP3 is intended to be a model starting point for analyses at the country level, but country-specific cost structures, epidemiological needs, and national priorities will generally lead to definitions of EUHC that differ from country to country and from the model in this Review. DCP3 is particularly relevant as achievement of EUHC relies increasingly on greater domestic finance, with global developmental assistance in health focusing more on global public goods. In addition to assessing effects on mortality, DCP3 looked at outcomes of EUHC not encompassed by the disability-adjusted life-year metric and related cost-effectiveness analyses. The other objectives included financial protection (potentially better provided upstream by keeping people out of the hospital rather than downstream by paying their hospital bills for them), stillbirths averted, palliative care, contraception, and child physical and intellectual growth. The first 1000 days after conception are highly important for child development, but the next 7000 days are likewise important and often neglected.
AB - The World Bank is publishing nine volumes of Disease Control Priorities, 3rd edition (DCP3) between 2015 and 2018. Volume 9, Improving Health and Reducing Poverty, summarises the main messages from all the volumes and contains cross-cutting analyses. This Review draws on all nine volumes to convey conclusions. The analysis in DCP3 is built around 21 essential packages that were developed in the nine volumes. Each essential package addresses the concerns of a major professional community (eg, child health or surgery) and contains a mix of intersectoral policies and health-sector interventions. 71 intersectoral prevention policies were identified in total, 29 of which are priorities for early introduction. Interventions within the health sector were grouped onto five platforms (population based, community level, health centre, first-level hospital, and referral hospital). DCP3 defines a model concept of essential universal health coverage (EUHC) with 218 interventions that provides a starting point for country-specific analysis of priorities. Assuming steady-state implementation by 2030, EUHC in lower-middle-income countries would reduce premature deaths by an estimated 4·2 million per year. Estimated total costs prove substantial: about 9·1% of (current) gross national income (GNI) in low-income countries and 5·2% of GNI in lower-middle-income countries. Financing provision of continuing intervention against chronic conditions accounts for about half of estimated incremental costs. For lower-middle-income countries, the mortality reduction from implementing the EUHC can only reach about half the mortality reduction in non-communicable diseases called for by the Sustainable Development Goals. Full achievement will require increased investment or sustained intersectoral action, and actions by finance ministries to tax smoking and polluting emissions and to reduce or eliminate (often large) subsidies on fossil fuels appear of central importance. DCP3 is intended to be a model starting point for analyses at the country level, but country-specific cost structures, epidemiological needs, and national priorities will generally lead to definitions of EUHC that differ from country to country and from the model in this Review. DCP3 is particularly relevant as achievement of EUHC relies increasingly on greater domestic finance, with global developmental assistance in health focusing more on global public goods. In addition to assessing effects on mortality, DCP3 looked at outcomes of EUHC not encompassed by the disability-adjusted life-year metric and related cost-effectiveness analyses. The other objectives included financial protection (potentially better provided upstream by keeping people out of the hospital rather than downstream by paying their hospital bills for them), stillbirths averted, palliative care, contraception, and child physical and intellectual growth. The first 1000 days after conception are highly important for child development, but the next 7000 days are likewise important and often neglected.
UR - http://www.scopus.com/inward/record.url?scp=85034810205&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(17)32906-9
DO - 10.1016/S0140-6736(17)32906-9
M3 - Review article
C2 - 29179954
AN - SCOPUS:85034810205
SN - 0140-6736
VL - 391
SP - 1108
EP - 1120
JO - The Lancet
JF - The Lancet
IS - 10125
ER -